peptides for long covid FAQ

Selank's anxiolytic effect is transient. It potentiates GABAergic tone while present but doesn't produce lasting structural changes like Semax does with neurogenesis. If improvement is real but temporary, consider two options: extended Selank use (28 days instead of 14) with slower taper, or address the underlying stress axis dysregulation driving the anxiety. Chronic cortisol elevation suppresses hippocampal function independently. Selank masks this but doesn't resolve it. Combination with adaptogenic compounds or HPA axis rebalancing protocols may extend benefit.

Consider vascular-dominant rather than neuroinflammatory-dominant brain fog. Semax targets BDNF restoration. If your primary deficit is cerebral hypoperfusion from endothelial dysfunction, BDNF upregulation won't improve oxygen delivery to neurons. Request SPECT or MRI perfusion imaging if accessible, or trial BPC-157 for 4–6 weeks targeting angiogenesis. Alternatively, if anxiety is prominent, Selank may address stress amplification Semax doesn't modulate. Non-response to Semax doesn't mean peptides don't work. It means the wrong mechanism was targeted.

Combination therapy makes mechanistic sense if both neuroinflammation and vascular dysfunction are present. Common in severe long COVID cases. No published trials test this combination, but the peptides act on distinct pathways with no known receptor overlap or metabolic interaction. Our team's approach: start Semax first (0.1% intranasal twice daily for 14 days) to address inflammation, assess response, then add BPC-157 (250 mcg subcutaneous twice daily for 30 days) if improvement plateaus below functional baseline. Staggering introduction allows attribution of effects. The Energy Mitochondria Fatigue Bundle incorporates this staggered multi-pathway approach for post-viral recovery.

Focus the protocol on BPC-157 and thymosin beta-4 rather than neurotropic peptides. Vascular-predominant Long COVID. Orthostatic intolerance, palpitations, poor perfusion. Responds to angiogenesis and endothelial repair mechanisms. BPC-157 restores nitric oxide signaling within 10–14 days in animal wound healing models, and TB-500 reduces inflammatory cytokines that perpetuate vascular inflammation. Combining both targets the problem from complementary angles: BPC-157 rebuilds vessel integrity while TB-500 clears the inflammatory environment preventing healing. Research dosing typically runs 12–16 weeks before assessing vascular function improvements.

Target mitochondrial function with MOTS-c rather than continuing vascular or neurological peptides. Isolated fatigue post-recovery suggests the cellular energy machinery hasn't restored normal oxidative phosphorylation. MOTS-c directly activates AMPK, the enzyme that signals mitochondria to increase ATP production through fat oxidation instead of glycolysis. Research dosing uses 5–15 mg subcutaneous 2–3 times weekly. Exercise capacity improvements in metabolic studies appear at 6–8 weeks. Our team has seen this pattern frequently. Patients who cleared brain fog and vascular symptoms but plateau at 70% energy often have residual mitochondrial impairment that energy-focused peptides can address.

Prioritize semax and selank over mitochondrial peptides. Brain fog without significant fatigue suggests the primary dysfunction is neuroinflammatory rather than metabolic. Semax crosses the blood-brain barrier and elevates BDNF. The molecule responsible for synaptic plasticity and memory consolidation. Selank reduces the inflammatory cytokines (IL-6, TNF-alpha) that impair hippocampal function. Russian research protocols use semax 300–600 mcg intranasal daily for 30–60 days, often paired with selank at the same dose for synergistic anti-inflammatory effects. Cognitive improvements typically emerge at week 4–6 as neuroplasticity mechanisms engage.

Administer them sequentially, not simultaneously. Use Semax in the morning (two to three drops per nostril) and Selank in early afternoon (two drops per nostril). The peptides operate through complementary mechanisms. Semax for neurotrophic support, Selank for GABAergic modulation and inflammation reduction. And combined protocols have been used safely in Russian post-viral rehabilitation studies since the 1990s. Start each peptide individually for one week before combining to isolate any adverse reactions.

Discard it and start a new vial. Peptides stored above 8°C for more than 12 hours undergo protein denaturation that cannot be reversed by refrigeration. The solution may appear normal but amino acid sequence fragmentation has already occurred, rendering it biologically inactive. This isn't wasteful caution. It's recognition that a degraded peptide produces zero therapeutic effect and creates false conclusions about efficacy.

Continue the protocol through week four before assessing efficacy. Semax's neurotrophic mechanism requires 14–21 days to produce measurable BDNF upregulation and synaptic remodeling. It's not a stimulant with same-day effects. Cognitive function tests (Trail Making Test, Digit Span) should be performed at baseline and week four to detect improvements that subjective assessment might miss. If no objective improvement appears by week six, verify peptide storage conditions and consider switching to a higher concentration or combined protocol with Selank.

Start with immune restoration before addressing neurological symptoms. Chronic immune activation and elevated inflammatory cytokines drive neuroinflammation. Treating the upstream immune dysfunction often reduces downstream cognitive issues without direct neuroprotective intervention. Thymalin should be the first-line research compound, with Cerebrolysin or Dihexa added after 4–6 weeks if cognitive symptoms persist despite normalized inflammatory markers. Combining immune and neuroprotective peptides simultaneously can obscure which intervention is driving improvement and complicates dosing adjustments.

BPC-157 is the mechanistically optimal starting point for vascular and mitochondrial dysfunction. The compound's ability to restore endothelial function and improve microvascular density addresses the root cause of exercise intolerance. Inadequate oxygen and nutrient delivery to tissues. Pair BPC-157 with mitochondrial support (CoQ10, NAD+ precursors, PQQ) to address both vascular and cellular energy deficits. Fatigue in long COVID is rarely a single-origin problem. It's the downstream result of vascular injury, mitochondrial impairment, and immune activation compounding each other.

Peptide-based interventions operate through different mechanisms than standard protocols (rest, pacing, antidepressants, physical therapy). If you've plateaued on conventional care, it likely means your pathology. Immune dysregulation, endothelial damage, or neuroinflammation. Requires targeted molecular intervention rather than symptom management. Research peptides address these mechanisms directly, but they require proper sourcing, dosing, and monitoring to assess efficacy. The gap between standard care and peptide protocols is mechanistic specificity. One addresses symptoms, the other addresses root pathology.